Chardan Capital Sets $8 Price Target on Tvardi Therapeutics
Benzinga reports Chardan Capital initiated coverage of Tvardi Therapeutics with a Buy rating.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.